Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial
Open Access
- 20 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 21 (1), 1-11
- https://doi.org/10.1186/s13063-020-4212-8
Abstract
Pregnancies in women with sickle cell disease (SCD) are associated with a higher risk of sickle and pregnancy complications. Limited options exist for treating SCD during pregnancy. Serial prophylactic exchange blood transfusion (SPEBT) has been shown to be effective in treating SCD outside pregnancy, but evidence is lacking regarding its use during pregnancy. The aim of this study is to assess the feasibility and acceptability of conducting a future phase 3 randomised controlled trial (RCT) to establish the clinical and cost effectiveness of SPEBT in pregnant women with SCD. The study is an individually randomised, two-arm, feasibility trial with embedded qualitative and health economic studies. Fifty women, 18 years of age and older, with SCD and a singleton pregnancy at ≤ 18 weeks’ gestation will be recruited from six hospitals in England. Randomisation will be conducted using a secure online database and minimised by centre, SCD genotype and maternal age. Women allocated to the intervention arm will receive SPEBT commencing at ≤ 18 weeks’ gestation, performed using automated erythrocytapheresis every 6–10 weeks until the end of pregnancy, aiming to maintain HbS% or combined HbS/HbC% below 30%. Women in the standard care arm will only receive transfusion when clinically indicated. The primary outcome will be the recruitment rate. Additional endpoints include reasons for refusal to participate, attrition rate, protocol adherence, and maternal and neonatal outcomes. Women will be monitored throughout pregnancy to assess maternal, sickle, and foetal complications. Detailed information about adverse events (including hospital admission) and birth outcomes will be extracted from medical records and via interview at 6 weeks postpartum. An embedded qualitative study will consist of interviews with (a) 15–25 trial participants to assess experiences and acceptability, (b) 5–15 women who decline to participate to identify barriers to recruitment and (c) 15–20 clinical staff to explore fidelity and acceptability. A health economic study will inform a future cost effectiveness and cost-utility analysis. This feasibility study aims to rigorously evaluate SPEBT as a treatment for SCD in pregnancy and its impact on maternal and infant outcomes. NIH registry (www.clinicaltrials.gov), registration number NCT03975894 (registered 05/06/19); ISRCTN (www.isrctn.com), registration number ISRCTN52684446 (retrospectively registered 02/08/19).Funding Information
- Research for Patient Benefit Programme (PB-PG-0317-20024)
This publication has 15 references indexed in Scilit:
- Sickle Cell DiseaseThe New England Journal of Medicine, 2017
- Sickle cell diseaseThe Lancet, 2017
- Spectra Optia® for Automated Red Blood Cell Exchange in Patients with Sickle Cell Disease: A NICE Medical Technology GuidanceApplied Health Economics and Health Policy, 2017
- Prophylactic versus selective blood transfusion for sickle cell disease in pregnancyEmergencias, 2016
- Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysisBlood, 2015
- The effects of exchange transfusion for prevention of complications during pregnancy of sickle hemoglobin C disease patientsTransfusion, 2015
- Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysisBlood, 2015
- Pregnancy outcome in patients with sickle cell disease in the UK – a national cohort study comparing sickle cell anaemia (HbSS) with HbSC diseaseBritish Journal of Haematology, 2014
- Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimatesThe Lancet, 2013
- Prophylactic Red-Cell Transfusions in Pregnant Patients with Sickle Cell DiseaseThe New England Journal of Medicine, 1988